Sjögren's disease & overlap diseases
Deep Immunophenotyping and Clustering Identifies Biomarkers Predictive of Lymphoma in Primary Sjögren Disease
Authors' conclusion
We unveil novel biomarkers of NHL in pSD based on an integrative analysis coupling deep immunophenotyping and clinical, biologic, and histopathologic data. Furthermore, these markers allow distinguishing B cell NHL subtypes in pSD.
Study context
- Population
- Patients with primary Sjögren disease fulfilling ACR/EULAR 2016 criteria
- Participants
- 206 patients
- Comparison
- Combination of CD11c+ FcRL5+ tissue-like memory B cells and IFNγ+ TNFα+ conventional T cells vs sum of conventional clinical and biologic markers for non-Hodgkin lymphoma (NHL) in pSD
- Outcome
- Biomarkers predictive of NHL in pSD
Methodological detailsdeep flow cytometry immunophenotyping, clustering
- Deep flow cytometry immunophenotyping
- Clustering
Performance
As reported in the abstract
Discrimination of NHL-pSD
| Test or model | Sensitivity | Specificity |
|---|---|---|
| Combination of two cell population abundances | 78.9% | 76.8% |
| Sum of conventional clinical and biologic markers | 68.4% | 78.0% |
Sensitivity
Combination of two cell population abundances78.9%
Sum of conventional clinical and biologic markers68.4%
Specificity
Combination of two cell population abundances76.8%
Sum of conventional clinical and biologic markers78.0%
Further findings
NHL subtypes
- CD11c+ FcRL5+ tissue-like memory B cells associated with mucosa-associated lymphoid tissue (MALT) marginal-zone NHL
- IFNγ+ TNFα+ conventional T cells more indicative of non-MALT B cell NHL
Original publication
Deep Immunophenotyping and Clustering Identifies Biomarkers Predictive of Lymphoma in Primary Sjögren Disease. Arthritis Rheumatol. Published 24 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →